Session: 621. Lymphomas: Translational—Molecular and Genetic: Poster II
Hematology Disease Topics & Pathways:
Research, adult, Translational Research, Lymphomas, non-Hodgkin lymphoma, genomics, B Cell lymphoma, Diseases, indolent lymphoma, Lymphoid Malignancies, Biological Processes, molecular biology, Technology and Procedures, Study Population, Human, pathogenesis, omics technologies
Formalin-fixed paraffin-embedded (FFPE) samples of EMZL were collected as part of the Atlas of Blood Cancer Genomes (ABCG) consortium. All cases underwent central pathology review by expert hematopathologists and diagnoses were confirmed as defined by the 2016 WHO classification. We defined global CN gains and losses at log2 fold change value of ±0.3, a value used by many CN tools. DNA and RNA WES were performed using the Illumina platform and DNA and RNA reads aligned to the GRCh38 genome and transcriptome, respectively. Exonic variants were identified and filtered using normal samples and population-based databases to identify putative driver mutations which were then aggregated at the gene level. Mutational analysis was done on samples that passed quality filtering.
225 unique diagnostic specimens were collected from 24 academic hematopathology departments. Cases originated from North America (USA and Canada, 86%), Europe (8%), and Asia (Singapore and China, 6%). 72 tumors were excluded due to inadequate mean coverage related to size of the biopsy or its quality. CN analysis and WES to identify non-silent mutations was performed in 153 unique EMZL including ocular adnexal (31), stomach (26), lung (23), salivary gland (23), and other extranodal locations (50). Average patient age was 63 years (range 53-71 years), female: male ratio of 1.6.
Mutation calls identified 718 variants (613 missense mutations and 105 truncating mutations) across 59 putative driver genes detected in ≥5% cases across all the anatomic locations. Among the most commonly mutated genes, we detected genes previously reported to be altered by targeted sequencing in EMZL (e.g., SPEN (12%), TNFAIP3 (A20) (8%), CREBBP (8%), TBL1XR1 (7%), and others) confirming our filtering strategy. A total of 44 focal CN alterations (24 gains and 20 CN losses) were detected for our set of recurrently mutated genes. Global CN gains included chromosome 3 (6%), 6p (7%), 8 (3%), 12 (4%), and 18 (5%) and losses in 21p (10%). Previously described tumor suppressor genes such as TNFAIP3 showed a typical pattern of alterations consisting of CN losses (6q23.3 deletion in 6%) and/or mostly truncating mutations (8%). Combining DNA mutations and CN alterations, the number of genetic lesions per tumor sample in the 59 putative driver genes ranged from 1 to 21, with an average load of 4.9 aberrations per case, consistent with previous genetic studies in other types of MZL lymphoma. The most frequent mutations across all sites were IGLL5 (22%), KMT2C (15%), KMT2D (14%), SPEN (12%), PRDM2 (11%), and NCOR1 (10%). Analysis using Elsevier Pathway Collection, BioPlanet 2019 and Go Biological Process 2021 revealed adjusted statistically significant enrichment of aberrations in genes in NOTCH signaling, DNA repair, cancer-associated sustaining of proliferative signaling, cancer associated histone methylation and positive regulation of transcription, by DNA-templated (GO:0045893) and RNA polymerase II (GO:0045944). Many of the mutated genes were previously not reported in EMZL. Some of the mutations were shared by tumors at different anatomic locations while some were more unique. Mutations in TET2, previous reported as specific for thyroid EMZL, were also detected in ocular adnexa, gastric and salivary gland MZL. Mutations in PTPRD, previously suggested as specific for NMZL, were detected also in EMZL. Overall, this analysis of a large number of samples from different anatomic locations further refines the mutational landscape in EMZL and provides novel clues on pathogenesis. More detailed analyses of mutations, CN variations and RNA expression will be presented at the meeting.
Disclosures: Alderuccio: ADC Therapeutics: Consultancy, Research Funding; Pyramid: Consultancy; Agios: Consultancy. Hsi: Eli Lilly: Research Funding; Astellas: Consultancy; Novartis: Consultancy; Abcon: Consultancy; Abbvie: Research Funding; Cytomx: Consultancy; Abcon: Current holder of stock options in a privately-held company; Virtuoso: Research Funding. Xu: Blueprint Medicines: Consultancy; Pure Marrow: Consultancy; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Consultancy. Koff: Atara BioTherapeutics: Research Funding; Gamida Cell: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Morphosys: Membership on an entity's Board of Directors or advisory committees; Oncternal Therapeutics: Research Funding; TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; Viracta Therapeutics: Research Funding. Cohen: Takeda: Research Funding; Genentech: Research Funding; BMS/Celgene: Research Funding; Astrazeneca: Consultancy, Research Funding; HutchMed: Consultancy, Research Funding; BeiGene: Consultancy, Research Funding; Janssen: Consultancy; Kite Pharma/Gilead: Consultancy; Lilly Oncology/Eli Lilly: Consultancy, Research Funding; Aptitude Health: Consultancy; Novartis: Research Funding. Love: Data Driven Biosciences: Consultancy, Current holder of stock options in a privately-held company. Louissaint: Lymphoma Research Foundation: Research Funding. Ong: SymBio Pharmaceuticals Limited: Research Funding. Chadburn: Leica Biosystems: Membership on an entity's Board of Directors or advisory committees; USCAP: Honoraria; Lieca Biosystems: Consultancy; NorthShore University HealthSystem (Eavanston IL: Honoraria; U Chicago: Honoraria. McKinney: Celgene: Consultancy; Incyte: Research Funding; Molecular Templates: Research Funding; UNUM: Research Funding; Epizyme: Consultancy; Genentech: Consultancy; Pharmacyclics: Consultancy; Beigene: Research Funding; Denovo Biopharma: Research Funding; Pharmacyclics: Research Funding; Nordic Nanovector: Research Funding; BMS: Research Funding; Genentech: Research Funding; Celgene: Research Funding; Atara: Research Funding; LOXO: Research Funding; Cellactor: Research Funding; Kite/Gilead: Honoraria; Seattle Genetics: Honoraria; Molecular Templates: Honoraria; BTG: Honoraria; Pharmacyclics: Honoraria; Verastem: Honoraria; Genentech: Honoraria; Celgene: Honoraria; Kite/Gilead: Speakers Bureau; ADC therapeutics: Speakers Bureau. Evans: Acerta/AstraZeneca: Research Funding; TG Therapeutics: Research Funding. Behdad: Leica: Honoraria; advisory committee: Membership on an entity's Board of Directors or advisory committees; Leica: Membership on an entity's Board of Directors or advisory committees; Lilly: Honoraria; Foundation Medicine/Roche China: Honoraria; Thermofisher scientific: Honoraria. Czader: Beckman Coulter: Membership on an entity's Board of Directors or advisory committees. Dave: Data Driven Biosciences: Current Employment, Divested equity in a private or publicly-traded company in the past 24 months; Lantern Pharma Inc.: Other: Data Driven Biosciences conducted some of Lantern Pharma's pre-clinical studies. Lossos: LRF: Membership on an entity's Board of Directors or advisory committees; Adaptive: Honoraria; NCI: Research Funding.
See more of: Oral and Poster Abstracts